Literature DB >> 26630548

Empiric Antibiotic Therapy for Severe Sepsis and Septic Shock.

Taku Oshima1, Yoshiyuki Kodama1, Waka Takahashi1, Yosuke Hayashi1, Shinya Iwase1, Takeo Kurita1, Daiki Saito1, Yoshihiro Yamaji1, Shigeto Oda1.   

Abstract

BACKGROUND: A retrospective study was conducted to investigate the validity and the effectiveness of early empiric antibiotic and de-escalation therapy for the treatment of severe sepsis and septic shock patients in the intensive care unit (ICU).
METHODS: Patients admitted to the ICU at Chiba University Hospital from January 1, 2010, to December 31, 2012, for the treatment of severe sepsis or septic shock were selected for analysis.
RESULTS: One-hundred and ten patients were enrolled for the analysis. Carbapenems were selected most frequently (57.3%), followed by cephalosporins (22.7%), and penicillins (21.8%). Empiric antibiotic therapy was appropriate for 85 (77.3%) patients. Mortality rates for patients with inappropriate empiric therapy was 36.8%, whereas mortality rates for patients with appropriate empiric therapy was 17.5%. Among the patients with appropriate empiric antibiotic administration, de-escalation was associated with lower mortality rates of 5.0% for severe sepsis and 9.7% for septic shock patients. The mortality rates for the no de-escalation group were 19.0% and 35.7%, respectively.
CONCLUSION: Empiric antibiotic therapy was acceptable for severe sepsis and septic shock patients treated in the ICU. The appropriate selection of empiric antibiotics was related to a greater rate of de-escalation and better survival. The risk of multi-drug-resistant bacterial infections was not as high as expected, but will need further attention in the future.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26630548     DOI: 10.1089/sur.2014.096

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  1 in total

Review 1.  Right first time!

Authors:  Emine Alp
Journal:  Ann Transl Med       Date:  2016-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.